Hypertension
Pipeline by Development Stage
Drug Modality Breakdown
Hypertension is a mature ~$223M Medicare Part D market with stable demand driven by established drug classes and aging population demographics.
Key Trends
- ARBs and ACE inhibitors dominate market share with complementary mechanisms
- Multiple LOE cliffs approaching (Clonidine, Bystolic, Diovan, Norvasc, Benicar) creating generic conversion risk
- Combination therapies (EDARBYCLOR, DIOVAN HCT) gaining traction to improve adherence
Career Verdict
Hypertension is a stable career choice for those seeking established, lower-risk roles in mature markets, but offers limited innovation upside compared to high-growth therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | CLONIDINE (Clonidine) | Gen Pharmaceuticals | $33M | 15% | LOE_APPROACHING | Declining | |
| 2 | EDARBYCLOR (Azilsartan kamedoxomil / Chlorthalidone) | R-Pharm US | $27M | 12% | PEAK | Stable | 5.2yr |
| 3 | BYSTOLIC (Nebivolol hydrochloride) | AbbVie | $24M | 11% | LOE_APPROACHING | Declining | |
| 4 | DIOVAN (Valsartan) | Novartis | $24M | 11% | LOE_APPROACHING | Declining | |
| 5 | NORVASC (Amlodipine besylate) | Viatris | $16M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
stable with generic pressure
declining (older agent)
growing (adherence driver)
stable with generic pressure
stable
Career Outlook
StableHypertension remains a high-volume, low-volatility career area with predictable patient demand, established treatment algorithms, and stable reimbursement. Patent cliffs (2025–2031) will accelerate generic conversion and reduce branded product margins, creating consolidation pressure and potential restructuring at smaller hypertension-focused companies (e.g., Jubilant, R-Pharm US). However, aging demographics and uncontrolled hypertension prevalence (~40% of diagnosed patients) ensure sustained market size and commercial need, making hypertension a secure choice for risk-averse professionals.
Breaking In
Join a regional sales or MSL role at a major player (AbbVie, Novartis, AstraZeneca) to build foundation in hypertension guidelines, formulary management, and long-term patient outcomes; avoid small generics firms (Gen Pharma, R-Pharm US) unless seeking manufacturing or operations experience.
For Experienced Professionals
Pivot toward Medical Affairs, HEOR, or managed care roles to command higher salaries ($300K+) and insulate against patent cliff revenue volatility; consider emerging markets or combination therapy pipeline leadership to drive career growth in a mature indication.
In-Demand Skills
Best For
Hiring Landscape
Hypertension hiring is concentrated in Commercial roles (1,346 openings, 69% of total), reflecting the mature market focus on sales, marketing, and managed care access over R&D. Top hiring companies—Johnson & Johnson (1,462), AbbVie (1,051), Takeda (1,048), and AstraZeneca (1,029)—are primarily in broader cardiovascular and specialty care portfolios, not hypertension-specific teams. Salary expectations favor Medical Affairs and Clinical Operations (~$300K+) over R&D (~$224K), signaling career progression opportunity in evidence generation and health outcomes roles.
Top Hiring Companies
By Department
Hypertension hiring favors Commercial and Medical Affairs professionals; R&D and manufacturing roles offer lower salary but higher stability in a mature, non-cyclical market.
On Market (16)
Approved therapies currently available
Competitive Landscape
108 companies ranked by most advanced pipeline stage
+78 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 21,447 patients across 50 trials
Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy
Occurrence of Dyskalemia With Treatment for Hypertension
Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy
Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy
The Efficacy of Qianglidingxuan Tablets in the Treatment of Hypertension
Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension
Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension
Manidipine Versus Amlodipine in Patients With Hypertension
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Chronic Hypertension and Pregnancy (CHAP) Project
Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients
Heart Outcomes Prevention and Evaluation 4
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy
Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients
Comparision of Blood Pressure Variability Between Amlodipine and Losartan
The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)
HIGH Altitude CArdiovascular REsearch in the ANDES
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
Zainidip in Renal Artery Stenosis
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
Related Jobs in Cardiovascular
Senior Director, Sales Training & Effectiveness
Digital Center of Excellence Project Manager
Vice President, Talent Management
Executive Director, Clinical Development
Associate Director, Marketing - HCC
Associate Director, Marketing - HCC
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.